NEW YORK, April 15, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Merck & Co., Inc. (NYSE: MRK), Magellan Health Services Inc.
(NASDAQ: MGLN), ABIOMED, Inc. (NASDAQ: ABMD), CONMED Corporation
(NASDAQ: CNMD), and Greatbatch, Inc. (NYSE: GB). Private wealth
members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:
http://www.analystsreview.com/1143-100free
Merck & Co., Inc. Analyst Notes
On April 11, 2014, Merck &
Co., Inc. (Merck) announced interim results from the ongoing
C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the
efficacy and safety of an all-oral, once-daily regimen combining
MK-5172 and MK-8742 among patients with chronic HCV Genotype 1
infection. According to the release, hard-to-cure patients who were
administered MK-5172/MK-8742 with and without ribavirin (RBV) for
12 or 18 weeks have shown sustained viral response, 4 to 8 weeks
after the completion of therapy. Dr. Eric
Lawitz, MD, Vice President of Scientific and Research
Development at The Texas Liver Institute, and Clinical Professor of
Medicine at University of Texas Health
Science Center in San Antonio
said, "There is still a need for further options for the most
difficult-to-cure patients, including those with cirrhosis and
HCV/HIV co-infection, These findings provide additional clinical
evidence regarding the potential of MK-5172/MK-8742 in treating a
broad spectrum of HCV patients." The full analyst notes on Merck
& Co., Inc. are available to download free of charge at:
http://www.analystsreview.com/1143-MRK-.pdf
Magellan Health Services Inc. Analyst Notes
On April 7, 2014, Magellan Health
Services, Inc. (Magellan) announced the appointment of Daniel M. Parietti as CEO of AlphaCare, 65% of
which is owned by Magellan under a strategic investment which was
completed in December 2013. The
Company stated that under the new role which is effective from the
announcement date, Parietti reports directly to Scott Markovich, President of Magellan Complete
Care. "Daniel has an extensive background leading large successful
health plan businesses. His experience and proven track record,
coupled with AlphaCare's involvement in the New York market, will help us grow our
presence there," said Markovich. Magellan informed that prior to
joining AlphaCare, Parietti worked with Centene Inc. (Centene)
where he had executive leadership and profit and loss
responsibility for health plans in seven states. The full analyst
notes on Magellan Health Services Inc. are available to download
free of charge at:
http://www.analystsreview.com/1143-MGLN-.pdf
ABIOMED, Inc. Analyst Notes
On April 10, 2014, ABIOMED, Inc.
(ABIOMED) announced that it intends to release Q4 FY 2014 (period
ended March 31, 2014) financial
results on May 1, 2014. The Company
stated that it has scheduled a conference call at 8:00 a.m. ET on the same day to discuss the
results. ABIOMED informed that the conference call will be hosted
by the Company's Chairman, President, and CEO, Michael R. Minogue; and Vice President and CFO,
Robert L. Bowen. The Company noted
that the live webcast of the call will be available under the
Investors section of its website and replay of this conference call
will be available beginning at 11:00 a.m.
ET May 1, 2014 through
11:59 p.m. ET on May 8, 2014. The full analyst notes on ABIOMED,
Inc. are available to download free of charge at:
http://www.analystsreview.com/1143-ABMD-.pdf
CONMED Corporation Analyst Notes
On April 7, 2014, CONMED
Corporation (CONMED) announced that it intends to release Q1 2014
financial results on April 24, 2014,
before the market opens. The Company stated that it has scheduled a
conference call on the same day, which will be broadcast live over
the Internet at 10:00 a.m. ET, to
discuss the results. The Company informed that this webcast can be
accessed from CONMED's web site and replay of the call will be made
available through May 2, 2014.The
full analyst notes on CONMED Corporation are available to download
free of charge at:
http://www.analystsreview.com/1143-CNMD-.pdf
Greatbatch, Inc. Analyst Notes
On March 31, 2014, Greatbatch,
Inc. (Greatbatch) announced that will report its Q1 FY 2014 (period
ended April 4, 2014) financial
results through a press release on April 30,
2014, after the market closing. The Company stated that on
the same day it has scheduled a conference call at 5:00 p.m. ET to discuss the results. Greatbatch
added that the earnings conference call can be accessed from the
Company's website. The full analyst notes on Greatbatch, Inc. are
available to download free of charge at:
http://www.analystsreview.com/1143-GB-.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://www.analystsreview.com/
SOURCE Analysts Review